Navigation Links
OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib
Date:3/18/2008

fied by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the potential benefits of bevasiranib, our ability to establish OPKO's leadership position, our ability to aggressively engage in R&D activities and advance clinical testing of bevasiranib and our ability to develop a preclinical pipeline of novel agents for ophthalmic diseases, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those factors described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that enrollment of patients for the Phase III clinical trial for bevasiranib, may not be successful, that the Phase III clinical trial itself may not be completed on a timely basis or at all, that any of our compounds under development, including bevasiranib, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date
'/>"/>
SOURCE OPKO Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... in the course of a day - car, ... on the chemical industry to turn raw materials ... into valuable chemicals that are the ingredients of ... Sarina, who achieved outstanding progress in driving this ... using light instead of fossil fuels, has won ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... the latest addition to Clinovo’s CRO Partnership Program. With ... Program, Clinovo further expands its global reach to Latin ... we are now able to build studies on our ... also rely on Clinovo to fully support the solution ...
(Date:9/18/2014)... Mexico City, MX (PRWEB) September 18, 2014 ... event in Mexico City, MX. ASEA is the manufacturer ... drink and the skin care product, RENU28. , ... Samuelson, Regional Vice President Duvan Botero, and ASEA Field ... L. Samuelson holds a PhD in Atomic/Medical Physics from ...
(Date:9/17/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) was ... Young LLP ("EY") that it was resigning effective September 11, ... the Company on September 15, 2014 and reported in PDL,s ... PDL has issued the following statement in response to the ... on the reason for the resignation of EY.  We were ...
Breaking Biology Technology:Using solar energy to turn raw materials into ingredients for every day life 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3
... Thought leaders from around the world converge on ... Biomedical, Inc., a,medical technology company that markets the ... a Scientific Advisory Board. The,Board,s purpose is to ... of Provant, new product development, and further,application of ...
... DOYLESTOWN, Pa., May 20 Recognizing National,Hepatitis B Awareness ... Foundation,and the Association of Asian Pacific Community Health Organizations,(AAPCHO) ... the Health Needs of Women and Children," on May ... Honda (CA) and Charles Dent (PA). It,will call urgent ...
... CALGARY, May 20 /PRNewswire-FirstCall/ - Oncolytics Biotech ... that it has been granted,U.S. Patent 7,374,752 ... Disorders." The claims cover pharmaceutical compositions,which comprise ... the Company with additional patent protection for,reovirus ...
Cached Biology Technology:Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 2Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 3Hepatitis B Foundation and AAPCHO Sponsor Congressional Briefing on 'Zero Tolerance for Hepatitis B' 2Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent 2
(Date:9/18/2014)... of camouflage: you don,t just blend in, the background ... uncommon as you might think. Kathryn Feller, from the ... larval life stages of many marine species are transparent. ... most creatures cannot make transparent. Feller explains that the ... eye unit with an opaque pigment to prevent light ...
(Date:9/17/2014)... the Arts and Humanities has received a $260,000 grant ... project, "The Boundaries of the Human in the Age ... a wide-ranging series of events aimed at exploring two ... artists and researchers who are exploring the boundaries of ... humanism, and the other involves the increasingly influential hypothesis ...
(Date:9/17/2014)... and their environmental impact recently scored a major win. ... on the bags, and Governor Jerry Brown is expected ... not yielding without a fight, according to an article ... newsmagazine of the American Chemical Society. , Alexander Tullo, ... campaign logged its first small victory in 1990 when ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Mellon Foundation awards grant for major project in the humanities and sciences 2
... (SACRAMENTO, Calif.) A new UC Davis study has found ... those who earn higher wages, adding to growing evidence that ... "Our study clarifies a link that has been assumed but ... study and professor in the UC Davis Center for Healthcare ...
... of a collaborative grant from the Samuel Waxman Cancer ... designed to kill non-Hodgkin lymphoma tumor cells. The breakthrough ... The Foundation-funded investigators include Ari Melnick, M.D., of Weill ... of Maryland and Gilbert Priv, Ph.D., of the University ...
...   , ... PRINCETON, N.J. , May 10 ... R&D services, announced today that it has created a new Discovery & ... immunology services, Biomarker Center of Excellence, and Genomics Laboratory. Leveraging its minority ...
Cached Biology News:UC Davis study links obesity with lowest earnings 2Scientists design new drug type to kill lymphoma cells 2Covance Establishes New Discovery & Translational Services Group 2Covance Establishes New Discovery & Translational Services Group 3
... Immunoprecipitation kit allows a rapid and ... active FLAG-tagged protein. The immunoprecipitation is ... is a highly specific monoclonal antibody ... use of affinity resin allows an ...
... CromoCenSC is a chromogenic medium ... count of Salmonella (except S. thyphi) ... bacteria. ,The detection takes a maximum ... biochemical tests, no sterilization during preparation ...
...
...
Biology Products: